Glenmark to conduct trials of potential Covid drug

Glenmark Pharmaceuticals on Thursday said it has become the first company in India to receive approval from DCGI to conduct clinical trials of Favipiravir antiviral tablets to treat COVID-19 patients. Having internally developed the API and the formulations for the product, the company received approval for conducting the trial on mild to moderate patients.

from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/3bQLFQg
>

Comments

Popular posts from this blog

China's video-game curbs shock stocks

Relief for lessors: Delhi high court directs DGCA to de-register 54 GoAir planes